QR Kod

Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor α Testing in Ovarian Cancer

Background: Folate receptor alpha (FRα), commonly expressed in epithelial ovarian cancers, is a clinically actionable biomarker following approval of the antibody–drug conjugate mirvetuximab soravtansine (MIRV). Pivotal trials showed that high FRα expression predicts MIRV benefit, creating the need...

Ful tanımlama

Kaydedildi:
Asıl Yazarlar: Kim Ma, Basile Tessier-Cloutier, Alon D. Altman, Mark S. Carey, Josee-Lyne Ethier, Susie Lau, Cheng-Han Lee, Laura Hopkins, Katharina Kieser, Aalok Kumar, Shuk On Annie Leung, Julie M. V. Nguyen, Helen MacKay, Jacob McGee, Lina Salman, Shannon Salvador, Cidalia Sluce, Luiza Tatar, Alicia A. Tone, Anna Tinker, Elizabeth Tremblay, Ana C. Veneziani, Danielle Vicus, Stephen Welch, Sharon Windsor Harker, Melica Nourmoussavi Brodeur
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: MDPI AG 2026-06-01
Seri Bilgileri:Current Oncology
Konular:
epithelial ovarian cancer
folate receptor alpha
mirvetuximab soravtansine
consensus statement
companion diagnostics
Online Erişim:https://www.mdpi.com/1718-7729/33/6/330
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller